These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 33974145)

  • 1. Harnessing Metabolomics to Describe the Pathophysiology Underlying Progression in Diabetic Kidney Disease.
    Hasegawa S; Inagi R
    Curr Diab Rep; 2021 May; 21(7):21. PubMed ID: 33974145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical metabolomics characteristics of diabetic kidney disease: A meta-analysis of 1875 cases with diabetic kidney disease and 4503 controls.
    Yuan Y; Huang L; Yu L; Yan X; Chen S; Bi C; He J; Zhao Y; Yang L; Ning L; Jin H; Yang R; Li Y
    Diabetes Metab Res Rev; 2024 Mar; 40(3):e3789. PubMed ID: 38501707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Mitochondria-Targeted Metabolic Tubular Injury in Diabetic Kidney Disease.
    Jiang H; Shao X; Jia S; Qu L; Weng C; Shen X; Wang Y; Huang H; Wang Y; Wang C; Feng S; Wang M; Feng H; Geekiyanage S; Davidson AJ; Chen J
    Cell Physiol Biochem; 2019; 52(2):156-171. PubMed ID: 30816665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease.
    Jung CY; Yoo TH
    Diabetes Metab J; 2022 Mar; 46(2):181-197. PubMed ID: 35385633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolomics as a tool for the early diagnosis and prognosis of diabetic kidney disease.
    Pereira PR; Carrageta DF; Oliveira PF; Rodrigues A; Alves MG; Monteiro MP
    Med Res Rev; 2022 Jul; 42(4):1518-1544. PubMed ID: 35274315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine metabolomics reveals biomarkers and the underlying pathogenesis of diabetic kidney disease.
    Luo M; Zhang Z; Lu Y; Feng W; Wu H; Fan L; Guan B; Dai Y; Tang D; Dong X; Yun C; Hocher B; Liu H; Li Q; Yin L
    Int Urol Nephrol; 2023 Apr; 55(4):1001-1013. PubMed ID: 36255506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Might hyperbaric oxygen therapy (HBOT) reduce renal injury in diabetic people with diabetes mellitus? From preclinical models to human metabolomics.
    Harrison LE; Giardina C; Hightower LE; Anderson C; Perdrizet GA
    Cell Stress Chaperones; 2018 Nov; 23(6):1143-1152. PubMed ID: 30374882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current updates on metabolites and its interlinked pathways as biomarkers for diabetic kidney disease: A systematic review.
    Das S; Devi Rajeswari V; Venkatraman G; Elumalai R; Dhanasekaran S; Ramanathan G
    Transl Res; 2024 Mar; 265():71-87. PubMed ID: 37952771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights into the role of immunity and inflammation in diabetic kidney disease in the omics era.
    Hu X; Chen S; Ye S; Chen W; Zhou Y
    Front Immunol; 2024; 15():1342837. PubMed ID: 38487541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum integrative omics reveals the landscape of human diabetic kidney disease.
    Liu S; Gui Y; Wang MS; Zhang L; Xu T; Pan Y; Zhang K; Yu Y; Xiao L; Qiao Y; Bonin C; Hargis G; Huan T; Yu Y; Tao J; Zhang R; Kreutzer DL; Zhou Y; Tian XJ; Wang Y; Fu H; An X; Liu S; Zhou D
    Mol Metab; 2021 Dec; 54():101367. PubMed ID: 34737094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Targeting of Mitochondria in Diabetic Kidney Disease.
    Cleveland KH; Schnellmann RG
    Pharmacol Rev; 2023 Mar; 75(2):250-262. PubMed ID: 36781216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update of pathophysiology and management of diabetic kidney disease.
    Lin YC; Chang YH; Yang SY; Wu KD; Chu TS
    J Formos Med Assoc; 2018 Aug; 117(8):662-675. PubMed ID: 29486908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What's New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances.
    Watanabe K; Sato E; Mishima E; Miyazaki M; Tanaka T
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiota and its metabolites - molecular mechanisms and management strategies in diabetic kidney disease.
    Mao ZH; Gao ZX; Liu DW; Liu ZS; Wu P
    Front Immunol; 2023; 14():1124704. PubMed ID: 36742307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolomics reveal mitochondrial and fatty acid metabolism disorders that contribute to the development of DKD in T2DM patients.
    Li L; Wang C; Yang H; Liu S; Lu Y; Fu P; Liu J
    Mol Biosyst; 2017 Oct; 13(11):2392-2400. PubMed ID: 28956034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Potential Serum Metabolic Biomarkers of Diabetic Kidney Disease: A Widely Targeted Metabolomics Study.
    Zhang H; Zuo JJ; Dong SS; Lan Y; Wu CW; Mao GY; Zheng C
    J Diabetes Res; 2020; 2020():3049098. PubMed ID: 32190695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of metabolomics and peptidomics reveals distinct molecular landscape of human diabetic kidney disease.
    Jiang X; Liu X; Qu X; Zhu P; Wo F; Xu X; Jin J; He Q; Wu J
    Theranostics; 2023; 13(10):3188-3203. PubMed ID: 37351171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic modification in diabetic kidney disease.
    Liu Z; Liu J; Wang W; An X; Luo L; Yu D; Sun W
    Front Endocrinol (Lausanne); 2023; 14():1133970. PubMed ID: 37455912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired Amino Acid Metabolism and Its Correlation with Diabetic Kidney Disease Progression in Type 2 Diabetes Mellitus.
    Zhu H; Bai M; Xie X; Wang J; Weng C; Dai H; Chen J; Han F; Lin W
    Nutrients; 2022 Aug; 14(16):. PubMed ID: 36014850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose- and Non-Glucose-Induced Mitochondrial Dysfunction in Diabetic Kidney Disease.
    Ito M; Gurumani MZ; Merscher S; Fornoni A
    Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.